Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2483) 2483
Publication (121) 121
Book Chapter (39) 39
Book Review (22) 22
Book / eBook (14) 14
Newsletter (12) 12
Conference Proceeding (9) 9
Magazine Article (7) 7
Dissertation (4) 4
Newspaper Article (3) 3
Data Set (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (940) 940
humans (881) 881
index medicus (702) 702
male (702) 702
monoamine oxidase (664) 664
monoamine oxidase inhibitors - pharmacology (644) 644
monoamine oxidase - metabolism (628) 628
pharmacology & pharmacy (621) 621
neurosciences (541) 541
rats (534) 534
mao-b (467) 467
mao (379) 379
chemistry, medicinal (373) 373
mao inhibitors (359) 359
biochemistry & molecular biology (343) 343
parkinson's disease (325) 325
female (322) 322
mao-a (296) 296
parkinsons-disease (290) 290
brain (258) 258
dopamine (251) 251
monoamine oxidase inhibitors - chemistry (250) 250
mice (246) 246
clinical neurology (240) 240
psychiatry (231) 231
dose-response relationship, drug (222) 222
analysis (204) 204
adult (198) 198
selegiline (198) 198
structure-activity relationship (184) 184
monoamine-oxidase (183) 183
serotonin (181) 181
selegiline - pharmacology (174) 174
middle aged (172) 172
derivatives (166) 166
monoamine oxidase inhibitors - therapeutic use (162) 162
inhibition (161) 161
depression (157) 157
kinetics (150) 150
parkinson disease - drug therapy (150) 150
alzheimer's disease (149) 149
deprenyl (149) 149
inhibitors (149) 149
monoamine oxidase inhibitors - chemical synthesis (144) 144
brain - enzymology (143) 143
l-deprenyl (140) 140
antidepressants (139) 139
chemistry, organic (139) 139
oxidases (138) 138
mao-b inhibitor (136) 136
metabolism (136) 136
monoamine oxidase - chemistry (136) 136
moclobemide (134) 134
oxidative stress (133) 133
rasagiline (129) 129
alzheimers-disease (127) 127
rats, sprague-dawley (126) 126
aged (125) 125
dopamine - metabolism (124) 124
mao-b inhibitors (123) 123
brain - drug effects (119) 119
molecular structure (119) 119
monoamine oxidase - genetics (118) 118
rat-brain (116) 116
neuroprotection (115) 115
models, molecular (113) 113
rats, wistar (111) 111
enzymes (108) 108
drug therapy (106) 106
rat (106) 106
brain - metabolism (105) 105
monoamine-oxidase-b (101) 101
double-blind (97) 97
serotonin - metabolism (95) 95
amine oxidase (94) 94
monoamine oxidase inhibitors (93) 93
chemistry, multidisciplinary (90) 90
mao inhibitor (86) 86
time factors (86) 86
in-vitro (84) 84
levodopa (83) 83
potent (82) 82
in vitro techniques (81) 81
neurology (77) 77
clorgyline (76) 76
disease (76) 76
monoamine oxidase inhibitors - metabolism (76) 76
physiological aspects (76) 76
research (76) 76
clorgyline - pharmacology (74) 74
drug design (74) 74
in-vivo (74) 74
mptp (74) 74
drug interactions (71) 71
binding (70) 70
biological evaluation (70) 70
neurodegenerative diseases (70) 70
toxicology (70) 70
molecular docking (69) 69
monoamine oxidase - drug effects (69) 69
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2496) 2496
German (18) 18
Japanese (13) 13
Russian (8) 8
French (5) 5
Korean (5) 5
Portuguese (4) 4
Czech (3) 3
Spanish (3) 3
Chinese (2) 2
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase
by Kumar, Vijay and Kumar, Bhupinder and Kumar, Vinod and Prashar, Vikash and Saini, Suresh and Dwivedi, Ashish Ranjan and Bajaj, Beenu and Mehta, Devashish and Parkash, Jyoti
European Journal of Medicinal Chemistry, ISSN 0223-5234, 09/2019, Volume 177, pp. 221 - 234
Alzheimer's disease (AD) is a multifactorial neurological disorder involving complex pathogenesis. Single target directed drugs proved ineffective and since... 
Acetylcholinesterase inhibitors | Diphenylpyrimidine | MAO inhibitors | Alzheimer's disease | Dual inhibitors | Neurological disorders | Acetylchollnesterase inhibitors | DESIGN | CHEMISTRY, MEDICINAL | ALZHEIMERS-DISEASE | CHOLINESTERASE-INHIBITORS | NEUROPROTECTION | MULTITARGET-DIRECTED LIGANDS | DONEPEZIL | BIOLOGICAL EVALUATION | POTENTIAL TREATMENT | MULTIPOTENT MAO | HYBRIDS | Alkynes - chemical synthesis | Cholinesterase Inhibitors - toxicity | Pyrimidines - chemical synthesis | Humans | Cholinesterase Inhibitors - chemistry | Cholinesterase Inhibitors - chemical synthesis | Structure-Activity Relationship | Monoamine Oxidase Inhibitors - chemical synthesis | Pyrimidines - chemistry | Monoamine Oxidase - chemistry | Pyrimidines - toxicity | Drug Design | Alkynes - pharmacology | Molecular Structure | Monoamine Oxidase Inhibitors - pharmacology | Catalytic Domain | Alzheimer Disease - drug therapy | Alkynes - chemistry | Acetylcholinesterase - chemistry | Pyrimidines - pharmacology | Molecular Dynamics Simulation | Monoamine Oxidase Inhibitors - toxicity | Cholinesterase Inhibitors - pharmacology | Alkynes - toxicity | Cell Line, Tumor | Molecular Docking Simulation | Monoamine Oxidase Inhibitors - chemistry | Kinetics | Oxidases | Molecular dynamics | Development and progression | Nervous system diseases | Enzyme inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Inhibitor design for monoamine oxidases
by Ramsay, Rona R
Current Pharmaceutical Design, ISSN 1381-6128, 2013, Volume 19, Issue 14, pp. 2529 - 2539
Flavin-containing monoamine oxidases (MAO A and MAO B) located on the outer membrane of mitochondria oxidise amines and generate hydrogen peroxide. Inhibitors... 
Steady-state kinetic analysis | Redox state | Monoamine oxidase | Structure-based drug design | Neurotransmitter levels | Covalently-bound FAD | Anti-depressant | structure-based drug design | METHYLENE-BLUE | covalently-bound FAD | LIGAND-BINDING | BENZYLAMINE ANALOGS | ACTIVE-SITE | ALZHEIMERS-DISEASE | redox state | neurotransmitter levels | SEROTONIN TOXICITY | IMIDAZOLINE LIGANDS | steady-state kinetic analysis | MAO-A | SPECIES-DIFFERENCES | PHARMACOLOGY & PHARMACY | monoamine oxidase | B-CATALYZED OXIDATION | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Humans | Models, Molecular | Substrate Specificity | Monoamine Oxidase - genetics | Monoamine Oxidase - chemistry | Drug Design | Molecular Structure | Monoamine Oxidase Inhibitors - chemistry | Kinetics | Binding Sites | Monoamine Oxidase - metabolism
Journal Article
Details down arrow
3. Full Text Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease
by Sang, Zhipei and Pan, Wanli and Wang, Keren and Ma, Qinge and Yu, Lintao and Liu, Wenmin
Bioorganic and Medicinal Chemistry, ISSN 0968-0896, 2017, Volume 25, Issue 12, pp. 3006 - 3017
A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase... 
MAO-B inhibitor | BuChE inhibitor | 3,4-Dihydro-2(1H)-quinoline-O-alkylamines | Blood-brain barrier | MAO-A inhibitor | Alzheimer's disease | AChE inhibitor | MONOAMINE-OXIDASE | TARGET-DIRECTED LIGANDS | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | MODEL | MULTIFUNCTIONAL AGENTS | HYBRIDS | Monoamine Oxidase Inhibitors - pharmacology | Cholinesterase Inhibitors - pharmacokinetics | Humans | Quinolines - chemistry | Cholinesterase Inhibitors - chemistry | Alzheimer Disease - drug therapy | Electrophorus | Cholinesterase Inhibitors - chemical synthesis | Alzheimer Disease - enzymology | Monoamine Oxidase Inhibitors - chemical synthesis | Quinolines - pharmacology | Blood-Brain Barrier - metabolism | Monoamine Oxidase Inhibitors - pharmacokinetics | Quinolines - chemical synthesis | Quinolines - pharmacokinetics | Animals | Cholinesterase Inhibitors - pharmacology | Butyrylcholinesterase - metabolism | Swine | Drug Design | Monoamine Oxidase Inhibitors - chemistry | Acetylcholinesterase - metabolism | Monoamine Oxidase - metabolism | Oxidases | Alkaloids | Enzyme inhibitors | Surface active agents | Analysis | Resveratrol | Quinoline | Acetylcholine | Drug therapy | High performance liquid chromatography
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease
by Guzior, Natalia and Więckowska, Anna and Panek, Dawid and Malawska, Barbara
Current Medicinal Chemistry, ISSN 0929-8673, 01/2015, Volume 22, Issue 3, pp. 373 - 404
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The available therapy is limited to the symptomatic treatment and its... 
Antioxidants | β-amyloid anti-aggregation properties | Multi-target-directed ligands | Inhibitors of monoamine oxidase A/B | Inhibitors of β-secretase | Neuroprotective properties | Alzheimer's disease | Cholinesterase inhibitors | TARGET-DIRECTED LIGANDS | CHEMISTRY, MEDICINAL | H-3 RECEPTOR ANTAGONISTS | antioxidants | beta-amyloid anti-aggregation properties | BIOCHEMISTRY & MOLECULAR BIOLOGY | HISTAMINE H3 RECEPTOR | inhibitors of monoamine oxidase A/B | neuroprotective properties | BETA-AMYLOID AGGREGATION | multi-target-directed ligands | MAO-B INHIBITION | DIMETHYLAMINOMETHYL-SUBSTITUTED CURCUMIN | PHARMACOLOGY & PHARMACY | cholinesterase inhibitors | DESIGNED MULTIPLE LIGANDS | inhibitors of beta-secretase | SELECTIVE ACETYLCHOLINESTERASE INHIBITORS | CHOLINESTERASE/MONOAMINE OXIDASE-INHIBITORS | PEPTIDE-INDUCED TOXICITY | Neuroprotective Agents - therapeutic use | Neuroprotective Agents - chemistry | Humans | Enzyme Inhibitors - pharmacology | Alzheimer Disease - drug therapy | Drug Discovery - methods | Alzheimer Disease - enzymology | Enzyme Inhibitors - therapeutic use | Animals | Neuroprotective Agents - pharmacology | Enzyme Inhibitors - chemistry | Alzheimer Disease - metabolism | Amyloid beta-Peptides - metabolism | Amyloid beta-Peptides - chemistry | Protein Aggregates - drug effects
Journal Article
Details down arrow
5. Clinical advances in monoamine oxidase inhibitor therapies
by Kennedy, Sidney H
1994, 1st ed., Progress in psychiatry., ISBN 9780880484749, Volume no. 43, xvi, 302
Monoamine Oxidase Inhibitors | Monoamine oxidase | Inhibitors | therapeutic use
Book
Details down arrow
6. Full Text Tautomerism of N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide – A new selective, highly potent and reversible MAO-B inhibitor
by Tzvetkov, Nikolay T and Stammler, Hans-Georg and Antonov, Liudmil
Journal of Molecular Structure, ISSN 0022-2860, 12/2017, Volume 1149, pp. 273 - 281
The tautomeric properties of an -(3,4-dichlorophenyl)-1 -indazole-5-carboxamide (NTZ-1006, ) derivative, developed as highly potent, reversible and selective... 
Optical spectroscopy | MAO-B inhibitors | Indazole-5-carboxamides | Parkinson's disease | Molecular modeling | Density functional theory | Tautomerism | Crystallography | PHOTOELECTRON-SPECTRA | EXCITED-STATE | HYDE SCORING FUNCTION | ALZHEIMERS-DISEASE | AB-INITIO | CHEMISTRY, PHYSICAL | DENSITY FUNCTIONALS | MONOAMINE-OXIDASE-B | AZA-DERIVATIVES | ELECTRONIC-STRUCTURE | PARKINSONS-DISEASE | Nervous system diseases | Analysis | Resveratrol | Medical research | Specific gravity | Hydrogen | Physiological aspects | Medicine, Experimental | Density functionals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Monoamine Oxidase A Inhibitor–Near-Infrared Dye Conjugate Reduces Prostate Tumor Growth
by Wu, Jason Boyang and Lin, Tzu-Ping and Gallagher, John D and Kushal, Swati and Chung, Leland W. K and Zhau, Haiyen E and Olenyuk, Bogdan Z and Shih, Jean C
Journal of the American Chemical Society, ISSN 0002-7863, 02/2015, Volume 137, Issue 6, pp. 2366 - 2374
Development of anti-cancer agents with high tumor-targeting specificity and efficacy is critical for modern multidisciplinary cancer research. Monoamine... 
CANCER-CELLS | THERAPY | CLORGYLINE | BONE METASTASIS | MODEL | MESENCHYMAL TRANSITION | HYPOXIA | CHEMISTRY, MULTIDISCIPLINARY | Monoamine Oxidase Inhibitors - pharmacology | Prostatic Neoplasms - pathology | Animals | Spectroscopy, Near-Infrared | Mice, Nude | Monoamine Oxidase - drug effects | Male | Cell Proliferation - drug effects | Mice | Coloring Agents - chemistry | Cell proliferation | MAO inhibitors | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The therapeutic potential of monoamine oxidase inhibitors
by Tipton, Keith F and Edmondson, Dale and Youdim, Moussa B. H
Nature Reviews Neuroscience, ISSN 1471-003X, 04/2006, Volume 7, Issue 4, pp. 295 - 309
Monoamine oxidase inhibitors were among the first antidepressants to be discovered and have long been used as such. It now seems that many of these agents... 
PROTEIN-KINASE-C | OXIDATIVE STRESS | MESSENGER-RNA | ANTI-PARKINSON DRUG | GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE | MAO-B INHIBITOR | L-DEPRENYL | RAT-BRAIN | SUBSTANTIA-NIGRA | NEUROSCIENCES | NEURODEGENERATIVE DISEASES | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Humans | Structure-Activity Relationship | Neurodegenerative Diseases - drug therapy | Monoamine Oxidase - chemistry | Animals | Signal Transduction - drug effects | Models, Biological | Monoamine Oxidase Inhibitors - metabolism | Signal Transduction - physiology | Monoamine Oxidase Inhibitors - chemistry | Cerebral Cortex - drug effects | Monoamine Oxidase - metabolism | Neurodegenerative Diseases - classification
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine
by Kitaichi, Yuji and Inoue, Takeshi and Nakagawa, Shin and Boku, Shuken and Izumi, Takeshi and Koyama, Tsukasa
European Journal of Pharmacology, ISSN 0014-2999, 2010, Volume 637, Issue 1, pp. 77 - 82
Monoamine oxidase inhibitors (MAO inhibitors) have been widely used as antidepressants. However, it remains unclear whether a difference exists between... 
β-Phenylethylamine | Serotonin | In vivo microdialysis | Noradrenaline | MAO-B (monoamine oxidase B) inhibitor | MAO-A (monoamine oxidase A) inhibitor | RAT STRIATUM | METAANALYSIS | TRACE AMINES | beta-Phenylethylamine | (-)-DEPRENYL | MICRODIALYSIS | MOCLOBEMIDE | MONOAMINE-OXIDASE INHIBITORS | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | AMPHETAMINE | BRAIN | Monoamine Oxidase Inhibitors - pharmacology | Picolinic Acids - pharmacology | Phenethylamines - metabolism | Rats | Male | Chromatography, High Pressure Liquid | Rats, Sprague-Dawley | Monoamine Oxidase Inhibitors - administration & dosage | Prefrontal Cortex - pathology | Extracellular Space - metabolism | Animals | Norepinephrine - metabolism | Prefrontal Cortex - drug effects | Serotonin - metabolism | Prefrontal Cortex - metabolism | Antidepressive Agents - administration & dosage | Antidepressive Agents - pharmacology | Drug Therapy, Combination | Monoamine Oxidase - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor
by Pisani, Leonardo and Muncipinto, Giovanni and Miscioscia, Teresa Fabiola and Nicolotti, Orazio and Leonetti, Francesco and Catto, Marco and Caccia, Carla and Salvati, Patricia and Soto-Otero, Ramon and Mendez-Alvarez, Estefania and Passeleu, Celine and Carotti, Angelo
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2009, Volume 52, Issue 21, pp. 6685 - 6706
In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles,... 
PROTEIN-BINDING SITES | OXIDATIVE STRESS | CHEMISTRY, MEDICINAL | RESOLUTION CRYSTAL-STRUCTURES | LOG-P | ALZHEIMERS-DISEASE | WATER-MOLECULES | MAO-B | NEURODEGENERATIVE DISEASES | 7-SUBSTITUTED COUMARINS | PARKINSONS-DISEASE | Mitochondria - enzymology | Humans | Brain - enzymology | Coumarins - chemistry | Structure-Activity Relationship | Monoamine Oxidase Inhibitors - chemical synthesis | Isoenzymes - metabolism | Cell Survival - drug effects | Monoamine Oxidase Inhibitors - pharmacology | Administration, Oral | Mice, Inbred C57BL | Solubility | Membranes, Artificial | Models, Molecular | Rats | Mitochondria - drug effects | Permeability | Blood-Brain Barrier - metabolism | Brain - drug effects | Coumarins - pharmacology | Animals | Coumarins - chemical synthesis | Cell Line, Tumor | Protein Binding | Mice | Monoamine Oxidase Inhibitors - chemistry | In Vitro Techniques | Isoenzymes - antagonists & inhibitors | Monoamine Oxidase - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Monoamine oxidase B inhibitors for the treatment of parkinsons disease: A review of symptomatic and potential disease-modifying effects
by Schapira, Anthony H.V
CNS Drugs, ISSN 1172-7047, 2011, Volume 25, Issue 12, pp. 1061 - 1071
Parkinson's disease is a disorder characterized pathologically by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.... 
Selegiline | Monoamine-oxidase-B-inhibitors | Neuroprotection | Safinamide | Parkinsons-disease | Rasagiline | OXIDATIVE STRESS | DELAYED-START TRIAL | PSYCHIATRY | COMPLEX I DEFICIENCY | MAO-B | CLINICAL NEUROLOGY | ANTI-ALZHEIMER DRUG | DOPAMINE NEURONS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | L-DEPRENYL | MOLECULAR-BASIS | RASAGILINE | Monoamine Oxidase Inhibitors - therapeutic use | Neuroprotective Agents - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Clinical Trials, Phase III as Topic | Animals | Neuroprotective Agents - pharmacology | Humans | Parkinson Disease - enzymology | Parkinson Disease - drug therapy | Monoamine Oxidase - metabolism | Randomized Controlled Trials as Topic | Usage | Parkinson's disease | Research | Drug therapy | MAO inhibitors | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease
by Wang, Li and Esteban, Gerard and Ojima, Masaki and Bautista-Aguilera, Oscar M and Inokuchi, Tsutomu and Moraleda, Ignacio and Iriepa, Isabel and Samadi, Abdelouahid and Youdim, Moussa B.H and Romero, Alejandro and Soriano, Elena and Herrero, Raquel and Fernández Fernández, Ana Patricia and Ricardo-Martínez-Murillo and Marco-Contelles, José and Unzeta, Mercedes
European Journal of Medicinal Chemistry, ISSN 0223-5234, 06/2014, Volume 80, pp. 543 - 561
The synthesis, biochemical evaluation, ADMET, toxicity and molecular modeling of novel multi-target-directed onepezil +  ropargylamine + 8- ydroxyquinoline ( )... 
Multifunctional drugs | ChE and MAO inhibitors | Fe/Cu/Zn chelators | Alzheimer's disease | In vivo scopolamine-induced long-term memory deficit | Donepezil + Propargylamine + 8-Hydroxyquinoline hybrids | In vivo scopolamine-induced long-term memory deficit | Memory - drug effects | Cholinesterase Inhibitors - toxicity | Hydroxyquinolines - chemistry | Humans | Male | Pargyline - analogs & derivatives | Cholinesterase Inhibitors - metabolism | Chelating Agents - therapeutic use | Indans - chemistry | Monoamine Oxidase Inhibitors - therapeutic use | Propylamines - chemistry | Monoamine Oxidase Inhibitors - pharmacology | Piperidines - chemistry | Pargyline - chemistry | Alzheimer Disease - drug therapy | Rats | Acetylcholinesterase - chemistry | Chelating Agents - pharmacology | Hep G2 Cells | Monoamine Oxidase Inhibitors - toxicity | Animals | Chelating Agents - toxicity | Cholinesterase Inhibitors - pharmacology | Monoamine Oxidase Inhibitors - metabolism | Molecular Docking Simulation | Chelating Agents - metabolism | Cholinesterase Inhibitors - therapeutic use | Acetylcholinesterase - metabolism | Monoamine Oxidase - metabolism | Animal experimentation | Enzyme inhibitors | Analysis | Quinoline | Enantiomers | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Discovery, Biological Evaluation, and Structure–Activity and −Selectivity Relationships of 6′-Substituted (E)‑2-(Benzofuran-3(2H)‑ylidene)‑N‑methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors
by Pisani, Leonardo and Barletta, Maria and Soto-Otero, Ramon and Nicolotti, Orazio and Mendez-Alvarez, Estefania and Catto, Marco and Introcaso, Antonellina and Stefanachi, Angela and Cellamare, Saverio and Altomare, Cosimo and Carotti, Angelo
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2013, Volume 56, Issue 6, pp. 2651 - 2664
The use of selective inhibitors of monoamine oxidase A (MAO-A) and B (MAO-B) holds a therapeutic relevance in the treatment of depressive disorders and... 
NEURODEGENERATIVE DISORDERS | OXIDATIVE STRESS | CHEMISTRY, MEDICINAL | ANALOGS | PROTEIN-LIGAND DOCKING | RESOLUTION | SAFINAMIDE | MAO-B INHIBITORS | DERIVATIVES | PARKINSONS-DISEASE | INSIGHTS | Monoamine Oxidase Inhibitors - pharmacology | Stereoisomerism | Humans | Benzofurans - pharmacology | Structure-Activity Relationship | Drug Discovery | Benzofurans - chemistry | Monoamine Oxidase - chemistry | Monoamine Oxidase Inhibitors - metabolism | Protein Conformation | Molecular Docking Simulation | Monoamine Oxidase Inhibitors - chemistry | Benzofurans - metabolism | Monoamine Oxidase - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
by Hansen, Allan K and Hansen, Allan K and Brooks, David J and Brooks, David J and Borghammer, Per and Borghammer, Per
Molecular Imaging and Biology, ISSN 1536-1632, 6/2018, Volume 20, Issue 3, pp. 356 - 360
Recent evidence suggests that the tau radiotracer [18F]THK-5351 displays high affinity for the monoamine oxidase type B (MAO-B) enzyme. Utilizing another... 
Neuroimaging | Tau | MAO-b | Medicine & Public Health | Flortaucipir | Imaging / Radiology | ALZHEIMER-DISEASE | MILD COGNITIVE IMPAIRMENT | NEUROMELANIN | F-18-AV-1451 | POSITRON-EMISSION-TOMOGRAPHY | TAU PET | TRACER | BRAIN MONOAMINE-OXIDASE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PROGRESSIVE SUPRANUCLEAR PALSY | PARKINSONS-DISEASE | Monoamine Oxidase Inhibitors - pharmacology | Humans | Female | Male | Aged | Carbolines - metabolism | Monoamine Oxidase - metabolism | Oxidases | Tracers (Biology) | Neurosciences | Binding | Radioactive tracers | Inhibitors | Patients | Amine oxidase (flavin-containing) | Cortex
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights